Tibsovo

Active Ingredient(s): Ivosidenib
FDA Approved: * July 20, 2018
Pharm Company: * AGIOS PHARMACEUTICALS INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Tibsovo Overview

Ivosidenib is an experimental drug for treatment of cancer. It is a small molecule inhibitor of IDH1, which is mutated in several forms of cancer. The drug is being developed by Agios Pharmaceuticals and is in phase III clinical trials. The FDA awarded orphan drug status for acute myeloid leukemia and cholangiocarcinoma.[1][bettersourceneeded] Ivosidenib was approved by the FDA for acute myeloid leukemia (AML) with an IDH1 mutation and is presently in a phase I...

Read more Tibsovo Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Ivosidenib

Recent Tibsovo Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Ivosidenib
  • Tablet: 250mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Tibsovo: (1 result)

Sorted by National Drug Code
  • 71334-100 Tibsovo 250 mg Oral Tablet, Film Coated by Agios Pharmaceuticals, Inc.

Other drugs which contain Ivosidenib or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 24 September 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 501 S. Cherry St, Suite 1100, Denver, CO, 80246, USA